



Myeloid Therapeutics Clinical & Commercial License
January 11, 2021 12:00 PM EST

Released : January 11, 2021 07:00

RNS Number : 1564L
MaxCyte, Inc.
11 January 2021

**Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement
to Advance Myeloid's Cell Therapy Programs**

Myeloid to utilize MaxCyte's Flow Electroporation® technology and EXPERT™ platform to advance its novel cell therapies to treat solid tumors, T cell lymphoma and glioblastoma

CAMBRIDGE, MA and GAITHERSBURG, MD, 11 January 2021 -Myeloid Therapeutics, Inc., a company harnessing and reprogramming myeloid cells to treat cancers, and MaxCyte, Inc., (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today announce the signing of a clinical and commercial licensing agreement.

Myeloid Therapeutics will obtain non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and EXPERT™ platform. This agreement enables Myeloid to advance its pipeline programs, including for engineered cell therapies targeting solid tumors, T cell lymphoma, and glioblastoma. In return, MaxCyte is entitled to receive undisclosed development and approval milestones, and sales-based payments, along with other licensing fees.

Myeloid's ATAK™ platform leverages the unique power of myeloid cells to help patients fighting cancers that, until now, have been very difficult to treat. By targeting myeloid cells, the technology allows for diverse applications and Myeloid's pipeline expansion is ongoing.

"We are very excited to be working with MaxCyte, an established leader in cell engineering. This agreement provides long-term access to MaxCyte's unique electroporation technology platform, representing an important enabling step in the continued clinical advancement of targeted cell-based therapies, for patients with few if no options," said **Daniel Getts, PhD, CEO of Myeloid**. "The ease of use and integration of MaxCyte instruments into our workflow allows us to envision rapid-same-day turnaround of cell treatments for patients presenting with aggressive tumors."

Doug Doerfler, President & CEO of MaxCyte, said: "We are proud to support Myeloid's work and are excited about the company's novel approach to engineering and harnessing the innate capabilities of the myeloid cell. This agreement represents an important achievement for MaxCyte as it expands the use of our next-generation technology platform to support engineering in novel cell types. Myeloid's ATAK™ technology is being developed for several critical applications in cancer."

MaxCyte's EXPERT instrument portfolio represents the next generation of leading, clinically validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the EXPERT platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics.

About Myeloid Therapeutics

Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAK™ platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners. Myeloid expects to enter the clinic with its two lead programs in the first half of 2021. For more information, visit <https://www.myeloidtx.com/>.

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

Myeloid Media Contact

Sarah Sutton
Glover Park Group
ssutton@gpg.com
+1 202-741-1990

MaxCyte Contacts:

MaxCyte Inc. +1 301-944-1660

Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer

Nominated Adviser and Joint Corporate Broker

Panmure Gordon +44 (0)20 7886 2500
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden

Joint Corporate Broker

Numis Securities Limited +44 (0)20 7260 1000
James Black
Duncan Monteith

Financial PR Adviser

Consilium Strategic Communications +44 (0)203 709 5700
maxcyte@consilium-com

Mary-Jane Elliott
Ashley Tapp
Chris Welsh

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCSFMFMSEFSEIF